A joint Call to Action 2.0, released by WHO and partners, calls for urgent actions by governments and donors to step up momentum to rapidly enhance coverage of TB preventive treatment for those in need.

The World Health Organization releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB.

DALLAS, June 17, 2021 -- Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicare’s in vitro hollow fiber model of tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.

The ‘Xpert Ultra’ molecular test has a greater capacity than its predecessor (‘Xpert MTB/RIF’) in detecting tuberculosis cases, either passively (i.e. people who attend the hospital with disease symptoms) or actively (searching for possible cases in the community among contacts of cases). This is the main conclusion of a study performed by ISGlobal, an institution supported by “la Caixa” Foundation, in collaboration with the Manhiça Health Research Centre (CISM), published in the European Respiratory Journal.

16 June 2021, Geneva, Switzerland - The Stop TB Partnership and Bamboo Capital Partners, an impact investing platform, signed a partnership agreement to support small- and medium-enterprises and start-ups, particularly from TB affected countries, developing impactful health technologies for TB, COVID-19, and TB co-morbidities.

Coronavirus activates a stem cell-mediated defense mechanism that reactivates dormant TB in a mouse model and has implications for developing new vaccines and avoiding a global TB pandemic, report investigators in The American Journal of Pathology.

STREAM is the first large-scale, multi-country clinical trial to investigate shortened regimens for multidrug-resistant TB (MDR-TB), and the first phase III trial to test the efficacy and safety of bedaquiline, a new drug with a novel mechanism of action, within a shortened treatment regimen.

Celebrating TB heroes during the COVID-19 pandemic.

Tuberculosis (TB) isn’t very common in the US, but worldwide it causes an immense amount of suffering.

Two new studies have cast unprecedented light on disease processes in tuberculosis, identifying key genetic changes that cause damage in the lungs and a drug treatment that could speed up recovery.